The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency Ablation

Summary

Background: This study aims to test whether 5% lidocaine patches can reduce Radiofrequency ablation-induced pain. Methods: The study will enroll patients with hepatocellular carcinoma and schedule a radiofrequency ablation procedure. 200 patients will be invited to allocate randomly into study or control groups: pretreatment with a 5% lidocaine patch (LidotopⓇ) (Group A); pretreatment with a placebo patch (Group B); The skin patch is applied before Radiofrequency ablation (RFA) while admission, and is changed every day till discharge. Pain severity is evaluated by a visual analog scale using a 10-point scale recorded by a study nurse before RFA and after the procedure. The demographic data, hepatocellular carcinoma characteristics, analgesics usage, patient satisfaction with pain control, and visual analog scale will be compared between the two groups. Anticipated results: Pretreatment with 5% lidocaine patches is an effective and straight method of reducing Radiofrequency ablation-induced pain to reduce analgesics usage and improve patient satisfaction with pain control.

Timeline

Start

2017-05-09

Primary completion

2018-04-30

Completion

2018-04-30

Outcome

Missed primary endpoint

paper VAS pain scores, the primary endpoint, were not significantly different between the two groups. PMID 41692439 ↗

Publications

• Chen CJ, Chen WY, Lin CY, Chiu YC, Chang YJ. The Effects of Lidocaine Patches on Post-Radiofrequency Ablation Pain in Patients With Hepatocellular Carcinoma. Cancer Med. 2026 Feb;15(2):e71581. doi: 10.1002/cam4.71581.

Drugs

Indications